Price T Rowe Associates Inc. MD purchased a new position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,009 shares of the company’s stock, valued at approximately $88,000.
Other large investors have also made changes to their positions in the company. BNP Paribas Financial Markets increased its position in shares of Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. PNC Financial Services Group Inc. acquired a new position in shares of Pulse Biosciences during the fourth quarter worth $242,000. Inspire Investing LLC increased its position in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after acquiring an additional 10,039 shares during the period. Griffin Asset Management Inc. increased its position in shares of Pulse Biosciences by 15.7% in the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after acquiring an additional 40,700 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after acquiring an additional 189,227 shares during the period. 76.95% of the stock is owned by institutional investors and hedge funds.
Pulse Biosciences Price Performance
NASDAQ PLSE opened at $19.01 on Monday. The stock’s fifty day moving average price is $14.39 and its 200 day moving average price is $10.94. Pulse Biosciences, Inc. has a 1 year low of $3.78 and a 1 year high of $20.44. The company has a market cap of $1.16 billion, a price-to-earnings ratio of -23.47 and a beta of 1.75.
Analyst Ratings Changes
Check Out Our Latest Stock Analysis on PLSE
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
- Five stocks we like better than Pulse Biosciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- This Small Cap Wealth Management Stock Could Provide Big Returns
- Find and Profitably Trade Stocks at 52-Week Lows
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Best Stocks Under $5.00
- MarketBeat Week in Review – 8/12 – 8/16
Want to see what other hedge funds are holding PLSE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pulse Biosciences, Inc. (NASDAQ:PLSE – Free Report).
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.